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Introduction
Experimental studies with NMDA receptor antagonists,
such as magnesium and memantine, have demonstrated
the ability of these substances to inhibit nociceptive trigem-
inal neurotransmission in electrophysiological studies.
Despite these promising experimental results clinical trials
results have been less than clear. To investigate further this
contrast using the open channel blockers, magnesium and
memantine, we studied their effects in a model of nocicep-
tive trigeminovascular activation.
Methods
Sprague-Dawley rats were anesthetized with pentobarbital
(60 mgkg-1) and cannulated for physiological monitoring,
maintenance of further anesthesia and drug administra-
tion. Anesthesia was maintained with intravenous propofol
(20-25 mgkg-1h-1). A cranial window was prepared over
the middle meningeal artery (MMA) and a bipolar elec-
trode was placed on the dura mater above the MMA for
electrical stimulation. For recording of neuronal activity a
tungsten electrode was introduced in the trigeminocervical
complex (TCC). Experimental groups received either
intravenously administered memantine (10 mgkg-1),
magnesium (100 mgkg-1) or vehicle.
Results
Magnesium and memantine did not have a significant
inhibitory effect on neuronal activity in the TCC. However,
blood pressure was significantly reduced after memantine
(31 ± 5 %, p < 0.05) or magnesium (49 ± 11 %, p < 0.05)
administration when compared to baseline.
Conclusion
The results indicate that the known inhibitory effect of
magnesium and memantine after microiontophoretic
application in the TCC could not be reproduced with
intravenous administration. This might be a result of the
low drug concentration that can be achieved with this
route of administration at the relevant site of action. A
further increase in dosage is not feasible since the used
dosage already led to significant reductions in arterial
blood pressure. The results support the clinical observa-
tions and provide a possible explanation for the lack of
consistent efficacy of these drugs for the treatment of
migraine.
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